Amgen, J&J planning Kyprolis-Darzalex combo studies

Amgen Inc. (NASDAQ:AMGN) and the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to evaluate combinations of Amgen's Kyprolis carfilzomib and

Read the full 236 word article

User Sign In